8th CongressGlobal Patients Globally Empowered Patients. Building the Momentum. Delegate Handbook 24-26 May 2018 - Marriott Dadeland Hotel, Miami (USA) www.iapo.org.uk/GPC2018 #GPC2018 Supported by Platinum Sponsors: Welcome Dear Congress Delegate, Above all, Congress offers It is my great pleasure, on behalf of IAPO’s Governing delegates the Board and Staff, to welcome you to the 8th opportunity to Global Patients Congress, the global event for patient meet or catch leaders and others working to improve the up, exchange lives of patients worldwide. information and ideas, and to It is encouraging to see that a top priority for many provide vital healthcare systems and health professionals is to input to IAPO’s explore a wide range of healthcare preferences with work and the patients and give them the opportunity to direction. participate in their own treatment by sharing the decision-making responsibility. This participation As IAPO Chair I (engagement) is empowering and that’s why this year’s look forward to Congress will focus on ‘Globally Empowered Patients. meeting and Building the momentum’. speaking with you, listening to your needs and working towards mutual aims over the coming days. I We will be show-casing best practice examples of am particularly pleased to welcome new members, patient engagement and empowerment within our who are crucial in helping us to strengthen the alliance, from the smallest members to the largest, global patients’ voice – we are sure you will benefit and multi-stakeholders. We will also look at how from attending the Congress. The IAPO Governing patients have been engaged and empowered by Board and Staff will be on hand during the Congress. healthcare financiers, manufacturers, suppliers, distributors and regulators. Delegates will be able to Best wishes, exchange ideas, engage with regional colleagues and draw on the energy and expertise of others to enhance their work. In addition, we will have keynote speakers and panelists, who will offer delegates new perspectives Jolanta Bilińska on patient engagement and empowerment from both IAPO Chair patient led and industry-led initiatives. About IAPO Mission The International Alliance of Patients’ IAPO’s mission is to help build patient-centred Organizations (IAPO) is the only global alliance healthcare worldwide by: representing patients across all disease areas ● and promoting patient-centred healthcare Realizing active partnerships with patients’ around the world. Our members are patients’ organizations, maximizing their impact organizations working at the international, through capacity building regional, national and local levels to represent ● Advocating internationally with a strong and support patients, their families and carers. patients’ voice on relevant aspects of healthcare policy, with the aim of influencing Vision international, regional and national healthcare IAPO’s vision is that patients throughout the agendas and policies world are at the centre of healthcare. ● Building cross-sector alliances and working collaboratively with like-minded medical Members and health professionals, policy-makers, IAPO has 265 members, representing 52 disease academics, researchers and industry areas and 71 countries. The impact of IAPO’s representatives voice is created by the diversity and breadth of members who drive our work towards patient- centred healthcare. 2 www.iapo.org.uk •• #GPC201#GPC20188 8th Global Patients Congress Theme Building the momentum to achieve The 8th Global Patients Congress has universal, patient-centred and been organised to look at patient sustainable access to health. engagement and patient empowerment within the healthcare Best practice reveals that patient engagement and empowerment cannot happen in a patchwork value chain to achieve Universal Health fashion and within siloes in a healthcare system. It Coverage. has to be all pervasive, systemic and systematic We have mapped best practice examples of patient along the entire healthcare value chain. It requires engagement and empowerment within our alliance collaborative partnerships between the patients, and multi-stakeholders. We have also looked at how their families, carers and patient organisations with patients have been engaged and empowered by the value chain: healthcare payers, providers, healthcare financiers, manufacturers, suppliers, pharmaceutical companies, producers and distributors and regulators. regulators. How will participants benefit? In 2015, 193 Member States of the UN General Assembly adopted resolution A/RES/70/1 Agenda for Participants will have the opportunity to explore the Sustainable Development 2030 and committed evidence base and best practice in: themselves to their populations, through Sustainable • Patient empowerment in Universal Health Development Goal 3, that they will ensure healthy Coverage lives and promote well-being for all at all ages by 2030. Target 3.8 is about delivering universal health • Patient empowerment in healthcare coverage which means that all individuals and regulation communities receive the health services they need • Patient empowerment in research and without suffering financial hardship. It includes the medicines development full spectrum of essential, quality health services, from health promotion to prevention, treatment, • Patient empowerment within global advocacy rehabilitation, and palliative care. and Pharma Participants will: • Input into IAPO direction and priorities • Showcase member initiatives, promoting peer-to-peer learning • Stimulate thinking around innovation and impact 24-26 May 2018 - Marriott Dadeland Hotel, Miami (USA) 3 With Thanks to the Congress Sponsors Platinum Sponsor: Pfizer Gold Sponsor: Novo Nordisk At Pfizer, we apply science and our global resources Novo Nordisk is a global healthcare company with to bring therapies to people that extend and 95 years of innovation and leadership in diabetes significantly improve their lives. We strive to set the care. This heritage has given us experience and standard for quality, safety and value in the capabilities that also enable us to help people discovery, development and manufacture of health defeat obesity, haemophilia, growth disorders and care products. Our global portfolio includes other serious chronic diseases. Headquartered in medicines and vaccines as well as many of the Denmark, Novo Nordisk employs approximately world's best-known consumer health care products. 42,700 people in 79 countries and markets its Every day, Pfizer colleagues work across developed products in more than 170 countries. For more and emerging markets to advance wellness, information, visit novonordisk.com, Facebook, prevention, treatments and cures that challenge the Twitter, LinkedIn, YouTube.www.novonordisk most feared diseases of our time. Consistent with our responsibility as one of the world's premier Gold Sponsor: Roche innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 160 years, we Roche is a global pioneer in pharmaceuticals and have worked to make a difference for all who rely diagnostics focused on advancing science to on us. www.pfizer.co.uk improve people’s lives. The combined strengths Platinum Sponsor: Teva of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in Teva Pharmaceutical Industries Ltd. is a leading oncology, immunology, infectious diseases, global pharmaceutical company that delivers high- ophthalmology and diseases of the central quality, patient-centric healthcare solutions used nervous system. Roche is also the world leader in by millions of patients every day. Headquartered in in vitro diagnostics and tissue-based cancer Israel, Teva is the world’s largest generic medicines diagnostics, and a frontrunner in diabetes producer, leveraging its portfolio of more than management. Founded in 1896, Roche continues 1,800 molecules to produce a wide range of to search for better ways to prevent, diagnose generic products in nearly every therapeutic area. and treat diseases and make a sustainable In specialty medicines, Teva has a world-leading contribution to society. The company also aims to position in innovative treatments for disorders of improve patient access to medical innovations by the central nervous system, including pain, as well working with all relevant stakeholders. Thirty as a strong portfolio of respiratory products. Teva medicines developed by Roche are included in integrates its generics and specialty capabilities in the World Health Organization Model Lists of its global research and development division to Essential Medicines, among them life- create new ways of addressing unmet patient saving antibiotics, antimalarials and cancer needs by combining drug development medicines. Roche has been recognised as the capabilities with devices, services and Group Leader in sustainability within the technologies. For more information, visit Pharmaceuticals, Biotechnology & Life www.tevapharm.com Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI). www.roche.com 4 www.iapo.org.uk/GPC2016www.iapo.org.uk • #GPC201 • 8 #GPC2016 m Silver Sponsor: Amgen Bronze Sponsor: Bayer Amgen is commited to unlocking